Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
PluvictoⓇ - PSMAfore study demonstrated statistically significant
and clinically meaningful radiographic PFS benefit; filing H2 2023
PSMAfore: Patients with mCRPC who progressed while on ARPI treatment | N=450
PLUVICTOⓇ
rPFS ✓
Primary
endpoint analysis
(at 175 events)
Final OS
Secondary
endpoint analysis
2025
Follow-up period
Once every 6 weeks for 6 cycles
for additional OS data
R
1:1
Change in Androgen Receptor
Pathway Inhibitor treatment
On a continuous basis
rPFS radiographic progression free survival. OS overall survival. mCRPC metastatic castration-resistant prostate cancer.
14 Investor Relations | Q4 2022 Results
INNOVATION
Study status
Met the primary endpoint (rPFS) - statistically significant and
clinically meaningful
First PSMA-targeted RLT to demonstrate clinical benefit
in patients with mCRPC who have not yet received taxane-based
chemotherapy
FDA regulatory submission planned for H2 2023, to include OS
data as aligned with FDA
Addressing a significant unmet need in earlier lines of metastatic
prostate cancer
NOVARTIS | Reimagining MedicineView entire presentation